Everything you always wanted to know about hepatitis B therapy

Therapy of Hepatitis B Virus Infections – Potential and Limitations

Editors
W.H. Gerlich
D. Glebe
L.G. Gürtler
R. Kaiser

Although the beginnings of hepatitis B therapy date back to 1976, it has only been in the last 10 years that it has gradually reached a satisfactory level of efficacy and dependency. According to the latest studies, many cases of chronic hepatitis B may need life-long therapy while others may reach, after several years, a kind of cure mediated by the host immune system. The main purpose of hepatitis B virus therapy is the prevention of the life-threatening late complications like liver cirrhosis and hepatocellular carcinoma, but it is also increasingly gaining a place in severe acute hepatitis and in the prevention of reactivation or transmission of the infection in various settings. This special issue of Intervirology contains contributions from internationally renowned virologists and hepatologists who describe these additional applications. Furthermore, the remaining problems and the latest approaches to overcome them are discussed. Primarily addressing clinical virologists and hepatologists, this publication is also relevant for those who are interested in therapy and prevention of infectious diseases, including public health specialists.

Contents
Preface

Background on Hepatitis B Virus
• Molecular Virology of Hepatitis B Virus and Targets for Antiviral Intervention: Glebe, D.; König, A.
• Genotypes and Genetic Variability of Hepatitis B Virus: Kramvis, A.

Therapeutic Targets
• Inhibitors of Hepatitis B Virus Attachment and Entry: Lempp, F.A.; Urban, S.
• Host Factor-Targeted Hepatitis B Virus Therapies: Gehring, A.; Bertoletti, A.; Tavis, J.E.

Clinical Applications
• Therapy of Hepatitis B Virus Infections: Potential and Limitations: Brunetto, M.R.; Bonino, F.
• Antiviral Therapy of Chronic Hepatitis B: van Bömmel, F.
• Therapy of Acute and Fulminant Hepatitis B: Tillmann, H.L.; Patel, K.
• Therapy of Occult Hepatitis B Virus Infection and Prevention of Reactivation: Raimondo, G.; Filomia, R.; Maimone, S.
• Prevention of Hepatitis B Virus Reinfection in Liver Transplant Recipients: Roche, B.; Samuel, D.
• Reduction of Infectivity in Chronic Hepatitis B Virus Carriers among Healthcare Providers and Pregnant Women by Antiviral Therapy: Gerlich, W.H.
• Effect of Antiretroviral HIV Therapy on Hepatitis B Virus Replication and Pathogenicity: Gürtler, L.G.

Resistance
• Mechanisms of Hepatitis B Virus Resistance Development: Warner, N.; Locarnini, S.
• Selected Phenotypic Assays Used to Evaluate Antiviral Resistance and Viral Fitness of Hepatitis B Virus and Its Variants: Glebe, D.; Geipel, A.
• Hepatitis B Virus Drug Resistance Tools: One Sequence, Two Predictions: Neumann-Fraune, M.; Beggel, B.; Kaiser, R.; Obermeier, M.

Author and Subject Index

The easiest way to order: www.karger.com/int

Orders may be placed with any bookseller, subscription agency, directly with the publisher or through a Karger distributor.

KARGER
Chemotherapy

International Journal of Experimental and Clinical Chemotherapy

Founded 1959 as 'Chemotherapia' by H.P. Kuemmerle and P. Rentchnick

Editor-in-Chief
G. Minotti, Rome

Associate Editors
G. Delogu, Rome
G. Graziani, Rome

Editorial Board
A.M. Biroccio, Rome
C. Chiesa, Rome
S. Gemma, Siena
S. Horkovics-Kovats, Kundl
S. Kohno, Nagasaki
C. Landersdorfer, Parkville, Vic.
P. Linder, Geneva
K. Machka, Munich
P. Menna, Rome
E. Monti, Busto Arsizio
K.G. Naber, Straubing
R. Nau, Göttingen
P. Preziosi, Rome
E. Salvatorelli, Rome
M. Sanguinetti, Rome
G. Sava, Trieste
G.M. Shah, Quebec, Que.
F. Sörgel, Nuremberg-Heroldsberg
J.C. Stingl, Bonn
F. Van Bambeke, Brussels
M. Wilhelm, Nuremberg

The founder of chemotherapy
Submission

Before submission, please read the Guidelines for Authors for specific requirements for manuscript preparation. Manuscripts written in English are considered and should be submitted online at www.karger.com/che (a link leads you to the Submission Website).

Submission of an article implies author agreement with the below Conditions. To be considered for publication, all manuscripts must be accompanied by a cover letter signed by all authors stating that the work has not been published, nor is it under consideration elsewhere, and that all authors approve the submission.

A Copyright Transfer Form, available on the Submission Website, with the corresponding author's original (handwritten) signature must be received by the editorial office. Please print and sign the form, and upload it during submission (or fax or scan and email) to make it legally binding.

Names, postal and e-mail addresses of 4 international experts in the appropriate area of research should accompany each manuscript. At the Editors' discretion, scientist(s) selected from this list may be invited to act as referees(s). Referees suggested should not be from the same institution as the author.

Presentation of manuscripts should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals [see International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (April 2010 version). Available from: http://www.ICMJE.org]. In case of problems with submission, please contact: che@karger.com

S. Karger AG – Medical and Scientific Publishers
Editorial Office ‘Chemotherapy’
Allschwilerstrasse 10
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434

Conditions

All manuscripts are subject to editorial and peer review. Manuscripts are received with the explicit understanding that the work has not been published (wholly or in part), and is not under simultaneous consideration in any language elsewhere. Furthermore, all authors have made substantial contributions and confirm that they have seen and approved the manuscript submission. Submission of an article for publication implies the transfer of the copyright from the author to Karger Publishers upon acceptance. Accepted papers become the permanent property of Karger Publishers and are not released for review by the editors if necessary. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Sections

Authors should indicate in the cover letter which manuscript type is being submitted for publication:

Original Papers: Fully documented reports of original research that must describe full sets of significant, original experiments in current anti-infective and antitumor chemotherapy research. Abstract, Introduction, Materials and Methods, Results, and Discussion sections are required. Consideration for publication is based on originality, novelty, scientific soundness, and appropriate analysis (maximum 3,000 words, 80 references, plus tables/figures).

Reviews: Comprehensive, state-of-the-art papers covering a timely topic by experts in the field (maximum 4,000 words, plus tables/figures, references). Reviews are usually invited by the Editor but may be unsolicited. Authors are asked to contact the Editor-in-Chief before submission in order to avoid clashes with other pending reviews. All reviews are subject to peer review. Unstructured abstract of no more than 200 words is required.

Novel Insights from Clinical Practice: The journal only considers case reports that provide significant new insights into a clinical problem or with an extremely unusual clinical course. Submissions can be based around a case or a number of similar cases. The most important aspect of the presentation is that it should provide a new perspective on a recognized clinical scenario or may represent an entirely new clinical condition. The novel aspects of the case(s) may be in the phenotype, the presentation, the investigation and/or the management. The manuscript should contain an unstructured abstract (maximum 150 words), introduction, case report and discussion section (maximum 2,000 words, maximum 2 tables or figures). Boxes containing bullet points on Established Facts (what is already known) and Novel Insights (new information gained) are required on the first page of the report. These should highlight the novelty of the clinical observation.

Small Communications: Short reports, brief laboratory observations, and preliminary communications can be submitted for accelerated publication under Short Communications. They must present new findings of sufficient importance to justify their accelerated acceptance. Such communications should represent complete, original studies and should be arranged in the same way as full length manuscripts (maximum 1,600 words).

Ethics

Research must comply with the guidelines for human studies and animal welfare regulations. Manuscripts reporting studies on human subjects should include evidence that the research was ethically conducted in accordance with the Declaration of Helsinki (World Medical Association; http://www.wma.net/en/30publications/10policies/b3/index.html). In particular, authors should state in the Materials and Methods section that subjects have given their informed written consent and that the study protocol was approved by an appropriate ethics committee. All patients should be identified by numbers or aliases, not by their real names. Authors should also state that animal experimentation was approved by an independent ethics committee. Copies of these guidelines and policy statements must be available for review by the editors if necessary.

Conflict of Interest

Authors are required to disclose any sponsorship or funding arrangements related to the research presented in the manuscript and any possible conflicts of interest. A possible conflict of interest does not preclude consideration of a manuscript for publication, but the Editor might consider it appropriate to publish the disclosed information with the paper. All forms of support and financial involvement should be listed in the Acknowledgements section of the paper. The cover letter should certify that all forms of conflict of interest by all authors were clearly identified by all authors stating that the work has not been published, nor is it under consideration elsewhere, and that all authors approve the submission.

Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. Karger Publishers defines plagiarism as reproduction of another work with at least 25% similarity and without citation.

If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Footnotes

Footnotes should be avoided. When essential, they should be numbered consecutively and appear at the foot of the appropriate page.

Acknowledgements: Include all sources of funding for the research presented in the manuscript and substantive contributions of individuals regarding the research or manuscript. All possible conflicts of interest should also be given here.

Abbreviations: Abbreviations (with the exception of those clearly well-established in the field) should be explained when they are first used. Abbr.

Units of measurement: Measurements should be expressed in SI units wherever possible.

Drug names: Use generic names of drugs (first letter: lowercase) whenever possible. Registered trade names (first letter: uppercase) should be marked with the superscript registered symbol ® or ™ when they are first mentioned.

Downloaded by: 54.70.40.11 - 11/18/2017 7:11:33 PM
This peer-reviewed online-only journal publishes original case reports covering the entire spectrum of oncology, including prevention, diagnosis, treatment, toxicities of therapy, supportive care, quality-of-life, and survivorship issues. The journal will also accept case reports dealing with the use of novel technologies, both in the arena of diagnosis and treatment. Supplementary material is welcomed. The intent of the journal is to provide clinicians and researchers with a tool to disseminate their personal experiences to a wider public as well as to review interesting cases encountered by colleagues all over the world. Universally used terms can be searched across the entire growing collection of case reports, further facilitating the retrieval of specific information.

Following the open access principle, the entire contents can be retrieved at no charge, guaranteeing easy access to this valuable source of anecdotal information at all times.
Antimicrobial Section

Original Papers

Mareković, I.; Bošnjak, Z.; Jakopović, M.; Boras, Z.; Janković, M.; Popović-Grle, S. (Zagreb)

190 Efficacy and Toxicity of High-Dose Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections: A Comparative Study of a Matched Series
Trifi, A.; Abdellatif, S.; Daly, F.; Mahjoub, K.; Nasri, R.; Oueslati, M.; Mannai, R.; Bouzidi, M.; Ben Lakhal, S. (Tunis)

Anticancer Section

Review

179 The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials
Li, G.; Gao, S.; Sheng, Z.; Li, B. (Weifang)

Original Papers

171 Gemcitabine and Capecitabine Combination Chemotherapy in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and/or Taxanes
Yao, G.; Cao, L.; Liu, M.; Chen, L.; Hu, X.; Ye, C. (Guangzhou)

197 Phase II and UGT1A1 Polymorphism Study of Two Different Irinotecan Dosages Combined with Cisplatin as First-Line Therapy for Advanced Gastric Cancer
Wang, W.; Huang, J. (Beijing); Tao, Y. (Xu Zhou); Lyu, X.; Yang, L.; Wu, D.; Tian, Y. (Beijing)

204 Chemotherapy Modulates Intestinal Immune Gene Expression Including Surfactant Protein-D and Deleted in Malignant Brain Tumors 1 in Piglets
Rathe, M.; Thomassen, M. (Odense); Shen, R.L.; Pontoppidan, P.E.L. (Copenhagen); Husby, S. (Odense); Müller, K. (Copenhagen); Kruse, T.A. (Odense); Sangild, P.T. (Copenhagen)

217 The Glasgow Prognostic Score Predicts Response to Chemotherapy in Patients with Metastatic Breast Cancer
Wang, D.; Duan, L.; Tu, Z.; Yan, F. (Shanghai); Zhang, C.; Li, X.; Cao, Y. (Ningbo); Wen, H. (Shanghai)

203 Erratum